If you have been reading about Pharmacokinetics and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
=== Pyridine carboxylic acids === Pyridine-2-carboxylic acid, pyridine-3-carboxylic acid, and pyridine-4-carboxylic acid are well established. They are colorless solids. The 3-isomer, also known as [nicotinic acid, is related to vitamin B6. They are typically produced commercially by oxidation of the corresponding methylpyridines.
=== Nancy Bartlett === Nancy Lynn Bartlett is played by Sandra Bernhard. Nancy is a part owner of the Lanford Lunch Box. She marries Arnie Thomas, but — after he eventually leaves her — she comes out as a lesbian. She frequently is seen dating women; her first girlfriend Marla is played by Morgan Fairchild. Nancy is never ashamed of her promiscuity, nor does she ever show any self-consciousness about her unusual behavior. She is one of the most self-confident characters in the series, often even more than Roseanne. Her tendency toward self-absorption seems to only be quelled while dating a woman or being around Jackie. Nancy turns out to be a loyal good friend to both Roseanne and Jackie throughout the series; however, she doesn't hesitate to reprimand them for their selfishness and cruelty when they treat their mother, Bev, so harshly that Bev ends up crying about it for days afterward while Nancy gives her support. Nancy appeared in a revival-era episode in 2018 in season 10, but did not appear on The Conners.
== Resistance == Resistance to zalcitabine develops infrequently compared with other nRTIs, and generally only occurs at a low level. The most common mutation observed in vivo is T69D, which does not appear to give rise to cross-resistance to other nRTIs; mutations at positions 65, 74, 75, 184 and 215 in the pol gene are observed more rarely.
The half-life of uranium-236 is too short for it to be primordial, though it has been identified as an extinct progenitor of its alpha decay daughter, thorium-232. Uranium-236 occurs in spent nuclear fuel when neutron capture on 235U does not induce fission, or as a decay product of plutonium-240. Uranium-236 is not fertile, as three more neutron captures are required to produce fissile 239Pu, and is not itself fissile; as such, it is considered long-lived radioactive waste. Uranium-234 is a member of the uranium series and occurs in equilibrium with its progenitor, 238U; it undergoes alpha decay with a half-life of 245,500 years and decays to lead-206 through a series of relatively short-lived isotopes. Uranium-233 undergoes alpha decay with a half-life of 160,000 years and, like 235U, is fissile. It can be bred from thorium-232 via neutron bombardment, usually in a nuclear reactor; this process is known as the thorium fuel cycle. Owing to the fissility of 233U and the greater natural abundance of thorium (three times that of uranium), 233U has been investigated for use as nuclear fuel as a possible alternative to 235U and 239Pu, though is not in widespread use as of 2022. The decay chain of uranium-233 forms part of the neptunium series and ends at nearly-stable bismuth-209 (half-life 2.01×1019 years) and stable thallium-205. Uranium-232 is an alpha emitter with a half-life of 68.9 years. This isotope is produced as a byproduct in production of 233U and is considered a nuisance, as it is not fissile and decays through short-lived alpha and gamma emitters such as 208Tl.
=== EU risk assessments === In 2002 the EU Scientific Committee on Veterinary Measures relating to Public Health (SCVPH) claimed that the use of beef growth hormones posed a potential health risk, and in 2003 the EU enacted Directive 2003/74/EC to amend its ban, but the US and Canada objected that the EU had not met WTO standards for scientific risk assessment. The EC claimed that the hormones remain in the tissue, specifically 17-beta estradiol. However, the EC found no clear link to health risks in humans for the other five hormones. The EC reported that high amounts of hormones had been found in areas around dense cattle lots. This increase in hormones in groundwater affected waterways and nearby wild fish. Hormone contamination of North American waterways would not, however, have any health impacts on European consumers.
Sources: en.wikipedia.org
In the second half of the 18th century, Britain, and later continental Europe and the United States, experienced the Industrial Revolution. This was the first time during which lead production rates exceeded those of Rome. Britain was the leading producer, losing this status by the mid-19th century with the depletion of its mines and the development of lead mining in Germany, Spain, and the United States. By 1900, the United States was the leader in global lead production, and other non-European nations—Canada, Mexico, and Australia—had begun significant production; production outside Europe exceeded that within. A great share of the demand for lead came from plumbing and painting—lead paints were in regular use. At this time, more (working class) people were exposed to the metal and lead poisoning cases escalated. This led to research into the effects of lead intake. Lead was proven to be more dangerous in its fume form than as a solid metal. Lead poisoning and gout were linked; British physician Alfred Baring Garrod noted a third of his gout patients were plumbers and painters. The effects of chronic ingestion of lead, including mental disorders, were also studied in the 19th century. The first laws aimed at decreasing lead poisoning in factories were enacted during the 1870s and 1880s in the United Kingdom.
== Diagnosis == Echocardiography is the preferred screening test in the diagnosis of PAH as it accurately estimates pulmonary pressures. Other causes of pulmonary hypertension, such as left heart disease (WHO group 2), pulmonary hypertension due to lung disease (such as COPD)(WHO group 3) and pulmonary hypertension due to chronic blood clots in the pulmonary arteries (WHO group 4) need to be ruled out. Some tests which are commonly used include a CT scan of the chest, ventilation perfusion scan or a CT angiography (to rule out pulmonary hypertension due to chronic blood clots), pulmonary function test, and a cardiac MRI. Cardiac MRI is the preferred test to evaluate right ventricular structure and function in PAH. Pulmonary function testing in PAH may show an obstructive or restrictive defect, and the diffusion capacity of carbon monoxide (used as a surrogate for gas exchange in the alveoli) is reduced. A sleep study helps to rule out sleep disordered breathing, such as sleep apnea, which may contribute to PAH. The N-terminal prohormone of brain natriuretic peptide (NT pro-BNP) may be monitored in those with PAH and is prognostic. A right heart catheterization to measure right heart pressure is required for the diagnosis of PAH.
Increased heart rate Vasodilation leading to decreased systemic vascular resistance, and high-output heart failure Elevated jugular venous pressure Dyspnea (shortness of breath) on exertion Paroxysmal nocturnal dyspnea Peripheral edema (swelling of lower legs) or generalized edema (swelling throughout the body) Dilated cardiomyopathy
Burkett (1984), award-winning correspondent for WABC-TV Matthew Cooper (1984), Time magazine White House correspondent and defendant in the Valerie Plame investigation Tom Watson (1984), journalist, entrepreneur Thomas Vinciguerra (1985), journalist, editor and author Naftali Bendavid (1986), Congress correspondent for The Wall Street Journal Susan Benesch (1986), journalist, free speech advocate Elizabeth Rubin (1987), journalist for The New York Times Magazine, sister of Bloomberg News executive editor James Rubin '82 Aram Roston (1988), investigative journalist Edward Lewine (1989), author and freelance journalist Sam Marchiano (1989), television sportscaster, documentarian and activist, daughter of sportscaster Sal Marchiano David Streitfeld (1989), book reporter for The Washington Post; winner of the 2013 Pulitzer Prize for Explanatory Reporting Caroline Glick (1991), Israeli journalist, editor, writer Warren St. John (1991), journalist for The New York Times and former CEO of Patch Michael J. Socolow (1991), broadcast journalist and professor at the University of Maine Jesse Eisinger (1992), Pulitzer Prize-winning reporter for ProPublica Jean H.
Sources: en.wikipedia.org
== Awareness == The Substance Abuse and Mental Health Services Administration hosts an annual health observance known as National Prevention Week. Every third week of May, they encourage communities across the country to unite to share stories about positive mental and behavioral health and the importance of implementing prevention methods. They also sponsor Recovery Month every September. Recovery Month aims to raise awareness about mental and substance use disorders and to honor individuals who recover, promoting the positive message that prevention works and that treatment is effective. International Overdose Awareness Day is on 31 August to remember those who have died from an overdose, to decrease the stigma of drug-related deaths, and to promote the prevention of overdose.
The need for elevated temperatures and pressures leads to high energy consumption and high capital investment costs. Disposal of unwanted by-products may be difficult and/or expensive and hazardous solvents may be required. In stark contrast, enzymatic reactions are performed under mild conditions of temperature and pressure, in water as solvent, and exhibit very high rates and are often highly specific. Moreover, they are produced from renewable raw materials and are biodegradable. In addition, the mild operating conditions of enzymatic processes mean that they can be performed in relatively simple equipment and are easy to control. In short, they reduce the environmental footprint of manufacturing by reducing the consumption of energy and chemicals and concomitant generation of waste. In the production of fine chemicals, flavors and fragrances, agrochemicals and pharmaceuticals an important benefit of enzymes is the high degree of chemoselectivity, regioselectivity and enantioselectivity which they exhibit. Particularly, their ability to catalyze the formation of products in high enantiopurity, by an exquisite stereochemical control, is of the utmost importance in these industries. Notwithstanding all these desirable characteristic features of enzymes, their widespread industrial application is often hampered by their lack of long term operational stability and shelf-storage life, as well as by their cumbersome recovery and re-use. These drawbacks can be generally overcome by enzyme immobilization.
=== Antisense pharmaceuticals === In the United States, the Food and Drug Administration (FDA) has approved the phosphorothioate antisense oligonucleotides fomivirsen (Vitravene) and mipomersen (Kynamro) for human therapeutic use in antisense therapy. To prevent degradation of the therapeutic oliogoneucleotides, chemical modification is usually required. The most common chemical modification on the oligonucleotides is adding a phosphorothioate linkage to the backbones. However, the phosphrothioate modification can be proinflammatory. Adverse effects including fever, chills or nausea have been observed after local injection of phosphrothioate modified oligonucleotides. Gapmers often utilize nucleotides modified with phosphorothioate (PS) groups. Miravirsen is an antisense phosphorothioate oligonucleotides that is additionally a locked nucleic acid gapmer. Other antisense oligonucleotides using phosphorothioates include afovirsen, aganirsen, alicaforsen, bepirovirsen, custirsen, drisapersen, eplontersen, evazarsen, gataparsen, inotersen, IONIS-GCCRRx, nusinersen, oblimersen, olezarsen, pelacarsen, sefaxersen, tofersen, and volanesorsen. First-generation anti-miRNA oligonucleotides utilized 2’-O-Methyl RNA nucleotides with phosphorothioate internucleotide linkages positioned at both ends to prevent exonuclease attack. This was also shown to have an effect on target affinity. Using the P-S mutation was shown to decrease the Tm of the oligonucleotide, which leads to a lower target affinity.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.